Cambridge Investment Research Advisors
IMUX icon

Cambridge Investment Research Advisors’s Immunic IMUX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,850
Closed -$54K – 4107
2026
Q1 		$54K Buy
+4,850
New +$43.4K ﹤0.01% 3853

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Cambridge Investment Research Advisors's IMUX Position: Q2 2026 in Review

Cambridge Investment Research Advisors sold out of Immunic (IMUX) in Q2 2026, closing a stake of 4,850 shares — an estimated $54K sold.

Cambridge Investment Research Advisors first reported a position in IMUX in Q1 2026 and held it in 1 quarter. The position peaked at $54K in Q1 2026. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • Cambridge Investment Research Advisors reported no remaining Immunic position as of Q2 2026 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 4,850 Immunic shares in Q2 2026, an estimated $54K.
  • Cambridge Investment Research Advisors first reported a position in Immunic in Q1 2026 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Immunic position peaked at $54K in Q1 2026.
  • 55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.